| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Katsuya Morita, Masahiro Hamamoto, Shigeaki Arai, Shigeo Kitayama, Masahiro Irifune, Michio Kawahara, Kenji Kihira, Toshihiro Doh. Inhibition of serotonin transporters by cocaine and meprylcaine through 5-TH2C receptor stimulation facilitates their seizure activities. Brain research. vol 1057. issue 1-2. 2006-01-04. PMID:16125150. |
for this purpose, cocaine, meprylcaine and lidocaine, all of which have different effects on sert, were used as convulsants and the effects of serotonin reuptake inhibitors (ssris), specific agonists and antagonists for 5-ht receptor subtypes were evaluated in mice. |
2006-01-04 |
2023-08-12 |
mouse |
| Swen Hesse, Ulrich Müller, Thomas Lincke, Henryk Barthel, Thomas Villmann, Matthias C Angermeyer, Osama Sabri, Katarina Stengler-Wenzk. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry research. vol 140. issue 1. 2006-01-03. PMID:16213689. |
we applied [123i]-2beta-carbomethoxy-3beta-(4-idiophenyl)tropane (beta-cit) and a brain-dedicated high-resolution single photon emission computed tomography (spect) system to quantify dopamine transporter (dat) and serotonin transporter (sert) availability. |
2006-01-03 |
2023-08-12 |
Not clear |
| Oliver Pogarell, Gabriele Poepperl, Christoph Mulert, Christine Hamann, Nikolai Sadowsky, Michael Riedel, Hans-Juergen Moeller, Ulrich Hegerl, Klaus Tatsc. SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 15. issue 5. 2005-12-30. PMID:16139170. |
serotonin and dopamine transporter (sert, dat) availabilities have prospectively been investigated using [123i]beta-cit and single photon emission computed tomography in subjects with obsessive-compulsive disorder under treatment with the selective serotonin reuptake inhibitor citalopram. |
2005-12-30 |
2023-08-12 |
human |
| Jill B Rhoden, Maud Bouvet, Sari Izenwasser, Dean Wade, Stacey A Lomenzo, Mark L Trudel. Structure-activity studies of 3'-4'-dichloro-meperidine analogues at dopamine and serotonin transporters. Bioorganic & medicinal chemistry. vol 13. issue 19. 2005-12-23. PMID:15993612. |
the structure-activity relationships of 3',4'-dichloro-meperidine were investigated at dopamine (dat) and serotonin transporters (sert). |
2005-12-23 |
2023-08-12 |
Not clear |
| David S Paterson, Eric G Thompson, Richard A Belliveau, Bobbie A Antalffy, Felicia L Trachtenberg, Dawna D Armstrong, Hannah C Kinne. Serotonin transporter abnormality in the dorsal motor nucleus of the vagus in Rett syndrome: potential implications for clinical autonomic dysfunction. Journal of neuropathology and experimental neurology. vol 64. issue 11. 2005-12-15. PMID:16254496. |
we analyzed binding to the serotonin transporter (sert) using the radioligand [(125)i]-rti-55 with tissue autoradiography in 7 rett and 5 controls in 9 cardiorespiratory-related nuclei. |
2005-12-15 |
2023-08-12 |
mouse |
| Jean Logan, Yu-Shin Ding, Kuo-Shyan Lin, Deborah Pareto, Joanna Fowler, Anat Biego. Modeling and analysis of PET studies with norepinephrine transporter ligands: the search for a reference region. Nuclear medicine and biology. vol 32. issue 5. 2005-12-07. PMID:15982584. |
the development of positron emission tomography (pet) ligands for the norepinephrine transporter (net) has been slow compared to the development of radiotracers for others systems, such as the dopamine (dat) or the serotonin transporters (sert). |
2005-12-07 |
2023-08-12 |
Not clear |
| Harish C Prasad, Chong-Bin Zhu, Jacob L McCauley, Devadoss J Samuvel, Sammanda Ramamoorthy, Richard C Shelton, William A Hewlett, James S Sutcliffe, Randy D Blakel. Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase. Proceedings of the National Academy of Sciences of the United States of America. vol 102. issue 32. 2005-12-05. PMID:16055563. |
these studies reveal cellular phenotypes associated with naturally occurring human sert coding variants and suggest that altered transporter regulation by means of pkg/p38 mapk-linked pathways may influence risk for disorders attributed to compromised 5-ht signaling. |
2005-12-05 |
2023-08-12 |
human |
| J Pratuangdejkul, B Schneider, P Jaudon, V Rosilio, E Baudoin, S Loric, M Conti, J-M Launay, P Manive. Definition of an uptake pharmacophore of the serotonin transporter through 3D-QSAR analysis. Current medicinal chemistry. vol 12. issue 20. 2005-12-05. PMID:16181139. |
since the plasma membrane 5-ht transporter (sert) is the major protagonist in regulating extracellular 5-ht concentration, sert is the target of most drugs interacting with the serotonergic system. |
2005-12-05 |
2023-08-12 |
Not clear |
| J Pratuangdejkul, B Schneider, P Jaudon, V Rosilio, E Baudoin, S Loric, M Conti, J-M Launay, P Manive. Definition of an uptake pharmacophore of the serotonin transporter through 3D-QSAR analysis. Current medicinal chemistry. vol 12. issue 20. 2005-12-05. PMID:16181139. |
here, we report structure-activity relationships (sar) and three-dimensional qsar (3d-qsar) studies of a library of 121 compounds including 5-ht analogs, harmanes, benzothiazoles, indanones, amphetamine derivatives and substrate-type 5-ht releasers, with the goal of identifying the structural determinants crucial for sert uptake. |
2005-12-05 |
2023-08-12 |
Not clear |
| Silvia Racca, Angela Spaccamiglio, Paola Esculapio, Giuliana Abbadessa, Luigi Cangemi, Francesco DiCarlo, Paolo Portaleon. Effects of swim stress and alpha-MSH acute pre-treatment on brain 5-HT transporter and corticosterone receptor. Pharmacology, biochemistry, and behavior. vol 81. issue 4. 2005-11-28. PMID:16023186. |
taking all together these data, we investigated the effects of the fst exposure and the effects of pre-treatment with alpha-msh on cortical synaptosomal serotonin transporter (sert) activity, corticosterone (cort) plasma levels and on glucocorticoid receptor (gr) occupancy and expression in rat hippocampus. |
2005-11-28 |
2023-08-12 |
rat |
| Una D McCann, Zsolt Szabo, Esen Seckin, Peter Rosenblatt, William B Mathews, Hayden T Ravert, Robert F Dannals, George A Ricaurt. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 9. 2005-11-07. PMID:15841106. |
in the present study, 23 abstinent mdma users and 19 non-mdma controls underwent quantitative positron emission tomography (pet) studies using [11c]mcn5652 and [11c]dasb, first- and second-generation serotonin transporter (sert) ligands previously validated in baboons for detecting mdma-induced brain serotonin neurotoxicity. |
2005-11-07 |
2023-08-12 |
human |
| Agnes Szilagyi, Krisztina Boór, Anna Székely, Péter Gaszner, Huba Kalász, Mária Sasvári-Székely, Csaba Bart. Combined effect of promoter polymorphisms in the dopamine D4 receptor and the serotonin transporter genes in heroin dependence. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology. vol 7. issue 1. 2005-11-01. PMID:16167465. |
dopamine d4 receptor (drd4) and serotonin transporter (sert) gene polymorphisms were studied, as possible genetic risk factors for substance dependence. |
2005-11-01 |
2023-08-12 |
Not clear |
| D R Thakker, F Natt, D Hüsken, H van der Putten, R Maier, D Hoyer, J F Crya. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Molecular psychiatry. vol 10. issue 8. 2005-10-27. PMID:15940298. |
selective serotonin reuptake inhibitors (ssris) are widely used antidepressant drugs that increase the extracellular levels of serotonin by blocking the reuptake activity of the serotonin transporter (sert). |
2005-10-27 |
2023-08-12 |
mouse |
| Jeffrey L Rausc. Initial conditions of psychotropic drug response: studies of serotonin transporter long promoter region (5-HTTLPR), serotonin transporter efficiency, cytokine and kinase gene expression relevant to depression and antidepressant outcome. Progress in neuro-psychopharmacology & biological psychiatry. vol 29. issue 6. 2005-10-27. PMID:16005136. |
this work examines data consistent with the hypothesis, specific to genetic and kinetic differences of the serotonin (5-ht) transporter (sert), as they may be linked to divergent antidepressant response (adr). |
2005-10-27 |
2023-08-12 |
human |
| Kazufumi Hirano, Takahiro Seki, Norio Sakai, Yasuhiro Kato, Hisakuni Hashimoto, Shinya Uchida, Shizuo Yamad. Effects of continuous administration of paroxetine on ligand binding site and expression of serotonin transporter protein in mouse brain. Brain research. vol 1053. issue 1-2. 2005-10-27. PMID:16051196. |
although ssris potently interfere with the activity of brain serotonin transporter (sert) after acute treatment, clinical improvement of psychiatric diseases is observed only after the repeated administration for several weeks (2-6 weeks). |
2005-10-27 |
2023-08-12 |
mouse |
| Yuan-Wei Zhang, Gary Rudnic. Cysteine-scanning mutagenesis of serotonin transporter intracellular loop 2 suggests an alpha-helical conformation. The Journal of biological chemistry. vol 280. issue 35. 2005-10-25. PMID:15994310. |
like other proteins involved in neurotransmitter transport, serotonin transporter (sert) activity is regulated by multiple intracellular signal transduction pathways. |
2005-10-25 |
2023-08-12 |
Not clear |
| Xiaoying Wang, Michael H Baumann, Heng Xu, Marisela Morales, Richard B Rothma. (+/-)-3,4-Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. The Journal of pharmacology and experimental therapeutics. vol 314. issue 3. 2005-10-21. PMID:15937150. |
we showed that the serotonin (5-ht) neurotoxin 5,7-dihydroxytryptamine (5,7-dht) reduces brain tissue 5-ht, decreases expression of 5-ht transporter (sert) protein, and increases expression of glial fibrillary acidic protein (gfap). |
2005-10-21 |
2023-08-12 |
rat |
| Xiaoying Wang, Michael H Baumann, Heng Xu, Marisela Morales, Richard B Rothma. (+/-)-3,4-Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. The Journal of pharmacology and experimental therapeutics. vol 314. issue 3. 2005-10-21. PMID:15937150. |
in contrast, doses of (+/-)-3,4-methylenedioxymethamphetamine (mdma) that decrease brain tissue 5-ht fail to alter expression of sert or gfap. |
2005-10-21 |
2023-08-12 |
rat |
| Xiaoying Wang, Michael H Baumann, Heng Xu, Marisela Morales, Richard B Rothma. (+/-)-3,4-Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. The Journal of pharmacology and experimental therapeutics. vol 314. issue 3. 2005-10-21. PMID:15937150. |
these findings indicate that a dosing regimen of mdma that depletes brain 5-ht does not alter sert protein expression or the distribution of sert between endosomes and the plasma membrane and does not produce detectable evidence for neurotoxicity. |
2005-10-21 |
2023-08-12 |
rat |
| Allan Lawrie, Edda Spiekerkoetter, Eliana C Martinez, Noona Ambartsumian, W John Sheward, Margaret R MacLean, Anthony J Harmar, Ann-Marie Schmidt, Eugene Lukanidin, Marlene Rabinovitc. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circulation research. vol 97. issue 3. 2005-10-20. PMID:16002749. |
loss of serotonin (5-hydroxytryptamine [5-ht]) receptors or of the serotonin transporter (sert) attenuates pulmonary hypertension in animals, and polymorphisms causing gain of sert function are linked to clinical pulmonary vascular disease. |
2005-10-20 |
2023-08-12 |
human |